# Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C

> **NCT02118012** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 24 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Chlorcyclizine HCl
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02118012
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-20
- **Primary completion:** 2014-03-20
- **Final completion:** 2016-09-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118012, "Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02118012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*